The Change of Coagulation Markers in Children With β-thalassemia Disease After Stem Cell Transplantation

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Nongnuch Sirachainan, Mahidol University
ClinicalTrials.gov Identifier:
NCT00789516
First received: November 10, 2008
Last updated: March 6, 2013
Last verified: March 2013
  Purpose

Hypercoagulable state is well recognized in patients with β-thalassemia. Evidences of hypercoagulability include abnormal expression of phosphatidylserine on red blood cell (rbc) surface and consequent increased platelet activation and thrombin generation. In addition, a reduction of anticoagulants i.e. proteins C and S and antithrombin (AT) was demonstrated. However, coagulable state in patients with β-thalassemia following stem cell transplantation (SCT) has not been characterized.


Condition
Thalassemia

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: The Change of Coagulation Markers in Children With β-thalassemia Disease After Stem Cell Transplantation

Resource links provided by NLM:


Further study details as provided by Mahidol University:

Primary Outcome Measures:
  • Level of protein C,S and AT, TAT, P1+2 and D-dimer [ Time Frame: 3 years ] [ Designated as safety issue: Yes ]

Biospecimen Retention:   Samples Without DNA

Blood


Enrollment: 60
Study Start Date: June 2006
Study Completion Date: December 2009
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
Normal control
2
B thalassemia regular transfusion
3
B thalassemia post transplantation

Detailed Description:

Hypercoagulable state is well recognized in patients with β-thalassemia. Evidences of hypercoagulability include abnormal expression of phosphatidylserine on red blood cell (rbc) surface and consequent increased platelet activation and thrombin generation. In addition, a reduction of anticoagulants i.e. proteins C and S and antithrombin (AT) was demonstrated. However, coagulable state in patients with β-thalassemia following stem cell transplantation (SCT) has not been characterized.Therefore, the objective is to compare coagulation markers and anticoagulants among β-thalassemics with and without SCT and normal control (NC).The subjects will be classified into 3 groups; β-thalassemia post SCT (Thal-SCT), β-thalassemia treated with regular transfusion (Thal-RT) and NC. Blood samples will be tested for annexin V (an index of abnormal expression of phosphatidylserine on rbc surface), markers of activation of coagulation system (thrombin antithrombin complex (TAT), prothrombin fragment (F1+2), and D-dimer) and anticoagulants (proteins C and S and AT).

  Eligibility

Ages Eligible for Study:   1 Year to 18 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

The subjects were classified into 3 groups; β-thalassemia post SCT (Thal-SCT), β-thalassemia treated with regular transfusion (Thal-RT) and NC.

Criteria

Inclusion Criteria:

Group 1: beta thalassemia major or beta thalassemia / Hb E who receive regular transfusion therapy (Thal- RT). The baseline Hct was more than 24% for at least 6 months.

Group 2: beta thalassemia major or beta thalassemia / Hb E post SCT (Thal-SCT) who were discontinued immunosuppressive drugs.

Group 3: Normal children (NC) who had normal Hb/Hct and MCV for age

Exclusion Criteria:

Children with beta thalassemia major or beta thalassemia / Hb E who have co-diseases such as immune hemolytic anemia, infection, or inflammatory diseases

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00789516

Locations
Thailand
Department of Pediatrics, Ramathibodi hospital
Bangkok, Thailand, 10400
Sponsors and Collaborators
Mahidol University
Investigators
Principal Investigator: Nongnuch Sirachainan, MD Ramathibodi Hospital, Mahidol University
  More Information

No publications provided

Responsible Party: Nongnuch Sirachainan, Associate Prof, Mahidol University
ClinicalTrials.gov Identifier: NCT00789516     History of Changes
Other Study ID Numbers: ID11-48-16
Study First Received: November 10, 2008
Last Updated: March 6, 2013
Health Authority: Thailand: Ethical Committee

Keywords provided by Mahidol University:
Coagulation markers, thalassemia disease post SCT

Additional relevant MeSH terms:
Thalassemia
Beta-Thalassemia
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Anemia
Hematologic Diseases
Hemoglobinopathies
Genetic Diseases, Inborn

ClinicalTrials.gov processed this record on October 19, 2014